Discontinued — last reported Q4 '25
Sherwin-Williams Interest Paid increased by 45.6% to $159.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 33.3%, from $119.80M to $159.70M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 7.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $94.20M | $71.90M | $100.30M | $76.10M | $101.80M | $89.00M | $104.20M | $113.00M | $106.70M | $104.40M | $92.40M | $107.50M | $106.10M | $108.70M | $84.60M | $119.80M | $99.60M | $123.90M | $109.70M | $159.70M |
| QoQ Change | — | -23.7% | +39.5% | -24.1% | +33.8% | -12.6% | +17.1% | +8.4% | -5.6% | -2.2% | -11.5% | +16.3% | -1.3% | +2.5% | -22.2% | +41.6% | -16.9% | +24.4% | -11.5% | +45.6% |
| YoY Change | — | — | — | — | +8.1% | +23.8% | +3.9% | +48.5% | +4.8% | +17.3% | -11.3% | -4.9% | -0.6% | +4.1% | -8.4% | +11.4% | -6.1% | +14.0% | +29.7% | +33.3% |